The YCC internal and external advisory groups have provided invaluable guidance in planning and evaluation of all the major initiatives since the last NCI CCSG review, particularly during the last three years since the appointment of Dr. Lynch as Director. The Director has modified and improved the network of decision-making and advisory groups to include: ? The Director's Mini-Cabinet (Mini-Cab) is composed of the Director, Deputy Directors, and Associate Directors and meets weekly to evaluate progress in strategic YCC initiatives. ? The Executive Committee meets weekly to evaluate progress of all important initiatives and includes institutional and Research Program Leaders, plus the Mini-Cab members. ? The Internal Advisory Board, comprised of three senior leaders from the Yale School of Medicine, meets periodically with the Director to review pivotal YCC activities. ? The External Scientific Advisory Board (ESAB) has been expanded with the addition of several experienced Cancer Center leaders and includes 16 members, with complementary expertise in basic, translational, and population sciences. In addition, on the advice of the ESAB we have developed and are continually refining a Strategic Plan. With careful planning and evaluation by advisory groups, the YCC has successfully initiated the Strategic Plan, the reorganization of the Research Programs and their leadership, the integration of the new Smilow Cancer Hospital, and the substantial improvements in the clinical trials infrastructure. These coordinated teams of advisors provide critical advice and guidance, both annually in the fall and ad-hoc as required, ensuring that the YCC can most effectively set priorities and pursue objectives that help shape of basic, clinical, prevention and translational research at Yale.

Public Health Relevance

Program Planning and Evaluation is crucial to the effective functioning and long-term strategic planning of the YCC. Input and guidance from external and internal advisory groups has encouraged the growth of the Center during the project period and will continue to develop the YCC's strengths moving forward.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016359-35
Application #
8755647
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-08-01
Budget End
2015-07-31
Support Year
35
Fiscal Year
2014
Total Cost
$34,789
Indirect Cost
$13,895
Name
Yale University
Department
Type
DUNS #
043207562
City
New Haven
State
CT
Country
United States
Zip Code
06520
Bonazzoli, Elena; Predolini, Federica; Cocco, Emiliano et al. (2018) Inhibition of BET Bromodomain Proteins with GS-5829 and GS-626510 in Uterine Serous Carcinoma, a Biologically Aggressive Variant of Endometrial Cancer. Clin Cancer Res 24:4845-4853
Villarroel-Espindola, Franz; Yu, Xiaoqing; Datar, Ila et al. (2018) Spatially Resolved and Quantitative Analysis of VISTA/PD-1H as a Novel Immunotherapy Target in Human Non-Small Cell Lung Cancer. Clin Cancer Res 24:1562-1573
Wadia, Roxanne J; Stolar, Marilyn; Grens, Clarice et al. (2018) The prevention of chemotherapy induced peripheral neuropathy by concurrent treatment with drugs used for bipolar disease: a retrospective chart analysis in human cancer patients. Oncotarget 9:7322-7331
De Feyter, Henk M; Behar, Kevin L; Corbin, Zachary A et al. (2018) Deuterium metabolic imaging (DMI) for MRI-based 3D mapping of metabolism in vivo. Sci Adv 4:eaat7314
Ventura, Alessandra; Vassall, Aaron; Robinson, Eve et al. (2018) Extracorporeal Photochemotherapy Drives Monocyte-to-Dendritic Cell Maturation to Induce Anticancer Immunity. Cancer Res 78:4045-4058
Xiao, Qian; Wu, Jibo; Wang, Wei-Jia et al. (2018) DKK2 imparts tumor immunity evasion through ?-catenin-independent suppression of cytotoxic immune-cell activation. Nat Med 24:262-270
Jagannath, Sundar; Laubach, Jacob; Wong, Ellice et al. (2018) Elotuzumab monotherapy in patients with smouldering multiple myeloma: a phase 2 study. Br J Haematol 182:495-503
Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :
Chae, Wook-Jin; Bothwell, Alfred L M (2018) Therapeutic Potential of Gene-Modified Regulatory T Cells: From Bench to Bedside. Front Immunol 9:303
Kim, Hanseul; Keum, NaNa; Giovannucci, Edward L et al. (2018) Garlic intake and gastric cancer risk: Results from two large prospective US cohort studies. Int J Cancer 143:1047-1053

Showing the most recent 10 out of 675 publications